{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:25:27Z","timestamp":1791012327510,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.ctrv.2007.10.003","type":"journal-article","created":{"date-parts":[[2008,2,22]],"date-time":"2008-02-22T16:46:37Z","timestamp":1203698797000},"page":"145-156","source":"Crossref","is-referenced-by-count":53,"title":["Biochemotherapy for the treatment of metastatic malignant melanoma: A systematic review"],"prefix":"10.1016","volume":"34","author":[{"given":"Caroline","family":"Hamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manya","family":"Charette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2007.10.003_bib1","unstructured":"Canadian Cancer Society\/National Cancer Institute of Canada. Canadian cancer statistics 2006. Toronto, Canada; 2006."},{"key":"10.1016\/j.ctrv.2007.10.003_bib2","series-title":"Cutaneous medicine and surgery","first-page":"1576","article-title":"Melanoma","author":"Arndt","year":"1996"},{"key":"10.1016\/j.ctrv.2007.10.003_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","article-title":"Cancer statistics, 2003","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2007.10.003_bib4","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/jnci\/dji289","article-title":"Annual report to the nation on the status of cancer, 1975\u20132002, featuring population-based trends in cancer treatment","volume":"97","author":"Edwards","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2007.10.003_bib5","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/cncr.10593","article-title":"Annual report to the nation on the status of cancer, 1973\u20131999, featuring implications of age and aging on US cancer burden","volume":"94","author":"Edwards","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.10.003_bib6","series-title":"Cancer: principles and practice of oncology","first-page":"1947","article-title":"Cutaneous melanoma","author":"Balch","year":"1997"},{"key":"10.1016\/j.ctrv.2007.10.003_bib7","first-page":"CD001215","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Crosby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2007.10.003_bib8","doi-asserted-by":"crossref","first-page":"A7506","DOI":"10.1200\/jco.2005.23.16_suppl.7506","article-title":"Long-term survival results of a randomized multinational phase III trial of dacarbazine (DTIC) with or without BCL-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma (MM). [abstract]","volume":"23","author":"Kirkwood","year":"2005","journal-title":"J Clin Oncol (Ann Meet Proc)"},{"key":"10.1016\/j.ctrv.2007.10.003_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced, metastatic melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib10","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib11","first-page":"31","article-title":"Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study","volume":"66","author":"Al-Sarraf","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ctrv.2007.10.003_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00395492","article-title":"Phase II evaluation of fractionated low and single high dose cisplatin in various tumors","volume":"107","author":"Schilcher","year":"1984","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib13","first-page":"367","article-title":"Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis","volume":"61","author":"Chary","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ctrv.2007.10.003_bib14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5","article-title":"Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases","volume":"66","author":"Jacquillat","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.10.003_bib15","first-page":"A1343","article-title":"Clinical value of the nitrosourea fotemustine in disseminated malignant melanoma: Overview on 1022 patients including 144 patients with cerebral metastases [abstract]","volume":"12","author":"Khayat","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib16","series-title":"American society of clinical oncology education book","first-page":"414","article-title":"Overview of medical treatments of metastatic malignant melanoma","author":"Khayat","year":"2000"},{"key":"10.1016\/j.ctrv.2007.10.003_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.1984.2.3.164","article-title":"Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma","volume":"2","author":"Luikart","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0921-4410(04)22033-6","article-title":"Chemotherapy, cytokines, and biochemotherapy for melanoma","volume":"22","author":"Eton","year":"2005","journal-title":"Cancer Chemother Biol Response Modif"},{"key":"10.1016\/j.ctrv.2007.10.003_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.hoc.2006.02.005","article-title":"Immunotherapy of melanoma","volume":"20","author":"Rietschel","year":"2006","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ctrv.2007.10.003_bib20","first-page":"133","article-title":"Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial","volume":"3","author":"Thomson","year":"1993","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2007.10.003_bib21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1200\/JCO.1994.12.4.806","article-title":"Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma","volume":"12","author":"Bajetta","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib22","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.1998.16.5.1743","volume":"16","author":"Falkson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer","volume":"85","author":"Rosenberg","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2007.10.003_bib24","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1993.11.10.1969","article-title":"Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma","volume":"11","author":"Sparano","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib25","first-page":"A714","article-title":"The modified group C experience \u2013 phase III randomized trials of IL-2 and IL-2\/LAK in advanced renal cell carcinoma and advanced melanoma [abstract]","volume":"10","author":"McCabe","year":"1991","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ctrv.2007.04.003","article-title":"Single-agent Interleukin-2 n the treatment of metastatic melanoma: a systematic review","volume":"33","author":"Petrella","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2007.10.003_bib27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.1995.13.2.502","article-title":"The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation","volume":"13","author":"Browman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib28","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1200\/JCO.2005.03.197","article-title":"Randomized phase II designs in cancer clinical trials: current status and future directions","volume":"23","author":"Lee","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib29","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"issue":"14S","key":"10.1016\/j.ctrv.2007.10.003_bib30","first-page":"A7259","article-title":"A meta-analysis of biochemotherapy (BCT) for the treatment of metastatic malignant melanoma (MM) [abstract]","volume":"22","author":"El-Maraghi","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib31","first-page":"A2847","volume":"22","author":"Atkins","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/annonc\/mdl007","article-title":"Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma","volume":"17","author":"Bajetta","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bjc.6600043","article-title":"Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)","volume":"86","author":"Atzpodien","year":"2002","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ctrv.2007.10.003_bib34","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.20.6.1600","article-title":"Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial","volume":"20","author":"Ridolfi","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib35","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1200\/JCO.2002.07.044","article-title":"Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial","volume":"20","author":"Eton","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib36","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.1999.17.3.968","article-title":"Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b","volume":"17","author":"Rosenberg","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib37","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1200\/JCO.2005.03.202","article-title":"Dacarbazine, cisplatin, and interferon alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group","volume":"23","author":"Keilholz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib38","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1054\/bjoc.2001.1731","article-title":"Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)","volume":"84","author":"Hauschild","year":"2001","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ctrv.2007.10.003_bib39","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1200\/JCO.1997.15.7.2579","article-title":"Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group","volume":"15","author":"Keilholz","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib40","unstructured":"Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated Intergroup trial [ASCO slide presentation on the Internet]. 2003 [cited 2007 January 9]. Available from: http:\/\/www.asco.org\/portal\/site\/ASCO\/menuitem.34d60f5624ba07fd506fe310ee37a01d\/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=23&abstractID=101244."},{"key":"10.1016\/j.ctrv.2007.10.003_bib41","first-page":"CD005413","article-title":"Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma","author":"Sasse","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2007.10.003_bib42","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0959-8049(03)00372-1","article-title":"Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients","volume":"39","author":"Chiarion-Sileni","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2007.10.003_bib43","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/bjc.1998.214","article-title":"Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-\u03b1) and interleukin (IL-2) in patients with metastatic melanoma","volume":"77","author":"Johnston","year":"1998","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ctrv.2007.10.003_bib44","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.1999.17.2.651","article-title":"Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma","volume":"17","author":"Richards","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib45","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1200\/JCO.1999.17.9.2752","article-title":"Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma","volume":"17","author":"O\u2019Day","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.10.003_bib46","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.1998.630","article-title":"Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a","volume":"78","author":"Hoffmann","year":"1998","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ctrv.2007.10.003_bib47","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2005.04.5344","article-title":"Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma","volume":"24","author":"Lewis","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T07:06:27Z","timestamp":1557299187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737207001570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0305737207001570"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2007.10.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}